BFG
UTHR icon

Bleakley Financial Group’s United Therapeutics UTHR Stock Holding History

Bleakley Financial Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,059
Closed -$374K – 977
2024
Q4 		$374K Buy
1,059
+389
+58% +$143K 0.01% 707
2024
Q3 		$240K Buy
+670
New +$226K 0.01% 873

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bleakley Financial Group's UTHR Position: Q1 2025 in Review

Bleakley Financial Group sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 1,059 shares — an estimated $374K sold.

Bleakley Financial Group first reported a position in UTHR in Q3 2024 and held it in 2 quarters. The position peaked at $374K in Q4 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Bleakley Financial Group reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bleakley Financial Group sold 1,059 United Therapeutics shares in Q1 2025, an estimated $374K.
  • Bleakley Financial Group first reported a position in United Therapeutics in Q3 2024 and held it in 2 quarters.
  • Bleakley Financial Group's United Therapeutics position peaked at $374K in Q4 2024.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.